YFYoshihiro Funaki

Yoshihiro Funaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshihiro Funaki has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Tomoya Harada

    Department of Multidisciplinary Internal Medicine, Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Yonago, Japan

    3 shared publications
  • Akira Yamasaki

    Department of Multidisciplinary Internal Medicine, Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Yonago, Tottori 683‑8503, Japan

    2 shared publications
  • Akira Yamasaki

    Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan

    2 shared publications
  • Hiroki Ishikawa

    Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan, Japan

    2 shared publications
  • Kosuke Yamaguchi

    Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-cho, Yonago 683-8504, Japan

    2 shared publications
  • Masahiro Kodani

    Department of Multidisciplinary Internal Medicine, Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Yonago, Tottori 683‑8503, Japan

    2 shared publications

Latest Publications

  • Open Access

    Safety and Withdrawal Period of Dietary Supplements Before Bronchoscopy

    by Naoki Kinoshita, Kosuke Yamaguchi, Tomoya Harada, Tomohiro Sakamoto, Yoshihiro Funaki, Masaaki Yanai, Yasuhiko Teruya, Yuki Hirayama, Takafumi Nonaka, Hiroki Ishikawa, et al.

    Background/Objectives: Dietary supplements are commonly used in Japan. Although some dietary supplements can affect perioperative conditions due to abnormalities in the blood coagulation system, there are no reports examining the duration of withdrawal and the risk of complications during bronchoscopy. We aimed to retrospectively review the safety and withdrawal periods of supplements prior to bronchoscopy in patients who regularly consumed dietary supplements. Methods: This single-center retrospective observational study was conducted at Tottori University Hospital. Patients who underwent bronchoscopy between January 2019 and December 2019 were validated and examined. We examined patient backgrounds, in-cluding age, sex, underlying conditions, use of antithrombotic agents, consumption of di-etary supplements and the specific types of dietary supplements consumed, and the type of bronchoscopy procedure. Data regarding the duration of dietary supplement with-drawal and complications during and after bronchoscopy were also collected. Results: A total of 351 bronchoscopy procedures were performed during the observation period. Of these, 69 (23.3%) bronchoscopies were performed on patients who regularly used dietary supplements. There were 19 cases of invasive bronchoscopy in patients who regularly used dietary supplements with bleeding risk. The median withdrawal period for the dietary supplements was 14 days. The incidence of bleeding complications from inva-sive bronchoscopy did not differ significantly among the groups divided according to whether they took antithrombotic agents or dietary supplements with bleeding risk. Conclusions: Based on this retrospective analysis, dietary supplements may be considered safe if there is sufficient time to avoid taking them before undergoing invasive bronchoscopy.

  • Open Access

    β-Tocotrienol Decreases PDGF-BB-Induced Proliferation and Migration of Human Airway Smooth Muscle Cells by Inhibiting RhoA and Reducing ROS Production

    by Aditya Sri Listyoko, Ryota Okazaki, Tomoya Harada, Miki Takata, Masato Morita, Hiroki Ishikawa, Yoshihiro Funaki, Akira Yamasaki

    Background: Tocotrienols exhibit antioxidant and anti-inflammatory activities. RhoA, a small GTPase protein, plays a crucial role in regulating contractility in airway smooth muscle (ASM). Previous studies have demonstrated that γ-tocotrienols reduce ASM proliferation and migration by inhibiting the activation of RhoA. In this present study, we investigate the effect of another vitamin E isoform, β-tocotrienols, on human ASM cell proliferation and migration stimulated by platelet-derived growth factor-BB (PDGF-BB). Methods: Human ASM cells were pre-treated with β-tocotrienol prior to being stimulated with PDGF-BB to induce ASM cell proliferation and migration. The proliferation and migration of PDGF-BB-induced human ASM cells were assessed using colorimetric and transwell migration assays. The intracellular ROS assay kit was employed to quantify reactive oxygen species (ROS) in human ASM cells. Additionally, we explored the effect of β-tocotrienols on the signaling pathways involved in PDGF-BB-induced ASM proliferation and migration. Results: β-tocotrienol inhibited PDGF-BB-induced ASM cell proliferation and migration by reducing RhoA activation and ROS production. However, in this present study, β-tocotrienol did not affect the signaling pathways associated with cyclin D1, phosphorylated Akt1, and ERK1/2. Conclusions: In conclusion, the inhibition of RhoA activation and ROS production by β-tocotrienol, resulting in the reduction in human ASM proliferation and migration, suggests its potential as a treatment for asthma airway remodeling.


  • Open Access

    Pembrolizumab‑induced aseptic meningitis in a patient with non‑small cell lung cancer: A case report and literature review of aseptic meningitis as an immune‑related adverse event

    by Genki Inui, Yoshihiro Funaki, Haruhiko Makino, Hirokazu Touge, Katsunori Arai, Keisuke Kuroda, Yuuki Hirayama, Ryohei Kato, Takafumi Nonaka, Kohei Yamane, et al.

    Aseptic meningitis is a rare immune‑related adverse event (irAE), which occurs during treatment with immune checkpoint inhibitors (ICIs). This condition has non‑specific symptoms and exhibits no clear signs on magnetic resonance imaging (MRI). There are only a few reports of aseptic meningitis caused by pembrolizumab treatment for non‑small cell lung cancer (NSCLC). The present study includes a report of such a case and a review of the related literature. A 67‑year‑old Japanese man received first‑line pembrolizumab treatment for NSCLC and subsequently developed severe nausea and vomiting. No significant findings were observed following a computed tomography (CT) scan, MRI of the brain and upper gastrointestinal tract, or upper gastrointestinal endoscopy. Cerebrospinal fluid analysis revealed lymphocyte infiltration and elevation of the IgG index, without indications of metastasis or infection, which suggested the presence of aseptic meningitis. The symptoms immediately improved following prednisolone treatment, and aseptic meningitis was diagnosed as an irAE related to pembrolizumab treatment. Given that aseptic meningitis can cause non‑specific symptoms, including headache and nausea, the possibility of an irAE should be considered in patients with non‑specific symptoms who are receiving ICIs, and a cerebrospinal fluid examination should be performed.


  • Open Access

    P8‐87: Clinical study of amrubicin‐induced interstitial lung disease in lung cancer patients with interstitial lung abnormality

    by Frank Cheau‐Feng Lin, Stella Chin‐Shaw Tsai, Jin-Yang Huang, Hiroki Ishikawa, Yoshihiro Funaki, Hiroto Yunaga, Yuriko Sueda, Tomohiro Sakamoto, Miki Takata, Tomoya Harada, et al.